GlassScriptPhysician profile
David O Holtz
NPI 1215907084
$2,808.95
in general payments reported to CMS, 2019-2025
33 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $366 · 2021: $80.15 · 2022: $596 · 2023: $347 · 2024: $575 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $363.10 | 2020-2024 | Ova1 |
| Merck Sharp & Dohme LLC | $299.91 | 2019-2025 | Lynparza, Keytruda |
| Astrazeneca Pharmaceuticals LP | $267.78 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $213.69 | 2022-2025 | Jemperli, Zejula |
| Clovis Oncology, INC. | $198.47 | 2019-2022 | |
| Abbvie INC. | $185.30 | 2019-2025 | |
| Stryker Corporation | $175.00 | 2022 | |
| Genmab U.S., INC. | $159.52 | 2022-2025 | Tivdak |
| Eisai INC. | $149.11 | 2020-2025 | |
| Tempus Ai, INC | $96.43 | 2024-2025 | Xt Cdx |
| Davol INC. | $79.57 | 2023-2024 | Arista Ah Flexitip |
| Novartis Pharmaceuticals Corporation | $60.40 | 2024 | |
| Immunogen, INC. | $52.92 | 2023 | Elahere |
| Daiichi Sankyo INC. | $46.81 | 2025 | Injectafer, Enhertu |
| Tesaro, INC. | $46.45 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $41.77 | 2022 | |
| Caris Mpi, INC. | $39.60 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $37.78 | 2019 | |
| Minerva Surgical, INC | $32.21 | 2022 | |
| Mylan Institutional INC. | $29.30 | 2019 | |
| Roche Diagnostics Corporation | $24.44 | 2019 | |
| Myriad Genetic Laboratories, INC. | $23.42 | 2024 | Myrisk |
| Baxter Healthcare | $22.84 | 2023 | Tisseel |
| Amgen INC. | $22.38 | 2019 | |
| Meditrina | $21.79 | 2022 | |
| Edwards Lifesciences Corporation | $20.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.35 | 2024 | Sancuso |
| Dysis Medical, INC. | $17.16 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.12 | 2024 | |
| Conmed Corporation | $15.52 | 2023 | Airseal |
| Lilly USA, LLC | $13.23 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Holtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.